small molecule

YCANTH

CANTHARIDIN

Loss of exclusivityFebruary 2041latest FDA-listed patent expiry

CompanyVerrica Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand name	YCANTH
Active ingredient	CANTHARIDIN
Strength	0.7%
Dosage form	SOLUTION
Route	TOPICAL
Modality	Small molecule
FDA approval	July 2023
Marketing status	RX

Listed patents

Patent	Expires	Type
12290651	February 2041	product
12233042	August 2038	product
11147790	August 2038	product
11052064	May 2035	product

Regulatory exclusivity

Code	Expires
NCE	July 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.